STAT
FEBRUARY 4, 2025
The National Cancer Institute (NCI) has had a taxpayer-funded drug development program for nearly 70 years, initiated at a time when there was no private investment in oncology drugs. taxpayers should stop funding clinical trials of industry-owned drugs. At this stage, U.S. Keytruda).
STAT
DECEMBER 13, 2024
Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short of goals set by the United Nations and most of the increase came from just two organizations, according to a new report.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 18, 2020
However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in 1982. In 1990, the US Food and Drug Administration (FDA) requested Astra to change Losec’s brand name to Prilosec, to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide).
European Pharmaceutical Review
JULY 13, 2023
3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. 2,10 This data can help to inform the optimal drug candidates to take forward into clinical trials and inform pre-clinical research to iteratively develop medications for different clinical indications.
pharmaphorum
OCTOBER 12, 2022
“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. He began his career in 1991 in the SAGEM group in the Telecom and Defence sectors where he worked for nearly 10 years in Research and Development projects.
European Pharmaceutical Review
JULY 4, 2024
4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2005 [cited 2024May]. 2012/1916). BMB Reports. 2017;50(3):111–6.
pharmaphorum
APRIL 13, 2021
She is an experienced executive in drug development and has over 30 years’ experience in the biotechnology and pharmaceutical industry. from September 2005 to August 2008. from September 2005 to August 2008. About the author. Dr Cindy Jacobs is president and chief medical officer of Achieve Life Sciences.
Expert insights. Personalized for you.
294 
Let's personalize your content